China allowed the conditional use of the vaccine developed by the Sinopharm company against the new type of coronavirus (Covid-19). Chen Shifei, the National Health Products Administration official, announced at a press conference that the approval was given for the conditional use of Sinopharm vaccine. The vaccine, which was produced with the inactivated virus and is planned to be made in two doses, was the first vaccine allowed to be widely used in China.
Immunologist Tao Lina said conditional use means research is ongoing and authorities could request more data on the safety and effectiveness of the vaccine in certain populations with different health profiles. Tao also noted that in this case, the use of the vaccine may be restricted in certain age groups.
While the authorities did not provide a figure for the price of the Sinopharm vaccine, Zheng Zhongwei, a National Health Commission official, stated that it would definitely be a price that could be met. It was stated that the vaccine produced by Sinopharm's Beijing Biological Products Institute is currently in the stage of mass production, but no information was given about the current production capacity.
The Chinese company Sinopharm announced that one of the vaccines developed against Covid-19 had 79,3 percent protection in the last stage experiments.
In the statement made on the website of Sinopharm's Beijing Institute of Biological Products, it was stated that the approval application was made for the Covid-19 vaccine after the third and final stage tests. While tests continue in China, more than one million people, including healthcare professionals, were made from vaccines developed by Chinese companies with urgent approval.
Source: China International Radio